IHS Chemical Week

EnviroTech :: Biotech

Sanofi-Aventis Signs Licensing Agreement with U.S. Biotech Firm

4:14 AM MDT | October 2, 2009 | Deepti Ramesh

Sanofi-Aventis (Paris) says it has entered into an exclusive global collaboration and licensing agreement with biotechnology company Merrimack Pharmaceuticals (Cambridge, MA) for MM-121, a monoclonal antibody in oncology. MM-121 is currently in Phase 1 clinical testing. Sanofi-Aventis will receive an exclusive worldwide license to develop, manufacture and commercialize MM-121, under the terms of the deal. Merrimack will retain potential co-promotion rights in the U.S. MM-121 is a pioneering monoclonal antibody which brings a new innovative approach to...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa